

# RICHARD D. PURCELL

Life Sciences Executive | Drug & Device Development, Regulatory Strategy, and Commercialization

Fair Haven, NJ • [732-492-1797] • [richard.purcell@dnahealthlink.com] • linkedin.com/in/richard-purcell-a849758

---

## EXECUTIVE SUMMARY

---

A life sciences leader with a career spanning drug discovery, clinical development, regulatory strategy, and commercialization. I carry therapeutics and platform technologies from the laboratory bench through FDA pathways and into the market, and I have founded and led operating companies and CROs, closed M&A and licensing transactions, and built the technology evaluation practices that de risk early stage investment.

A bench trained protein biochemist with peer reviewed publications and issued patents, I pair genuine scientific depth with the commercial judgment to grow businesses, place capital, and guide founders through the gap between innovation and market that most early companies never cross.

## CORE COMPETENCIES

---

Drug & Device Development • FDA Regulatory Strategy & Submissions (IND) • Clinical Operations • Business Development & Licensing • Mergers & Acquisitions • Technology Search & Due Diligence • Commercial Launch • Executive Leadership & P&L • Fundraising & Investor Relations

## CURRENT & RECENT EXPERIENCE

---

### LeagueMed | *Managing Director, Business Development*

2023 – Present

Digital multimedia investment platform financing emerging medical technology with capital from healthcare professionals.

- Lead technology search, evaluation, and due diligence across product development, regulatory pathways, financial condition, and legal compliance to qualify emerging companies for investment.
- Advise portfolio and prospect founders on IP development, regulatory planning, licensing, and commercial strategy following initial diligence.
- Shape platform operations, corporate and institutional partnerships, and investment content, authoring published analysis on medtech innovation, regulation, and finance.

### DNA Healthlink, Inc. | *Founder & President*

2005 – Present

Strategic consulting practice delivering executive leadership, business development, and commercialization to biopharma, medtech, and healthcare IT companies.

- Provide interim executive management with P&L responsibility, business development and licensing, clinical operations, and regulatory strategy to emerging companies, hospitals, and technology firms.
- Serve as the operating vehicle through which the executive and advisory engagements below were delivered.

### RespireRx Pharmaceuticals | *SVP, Research & Development / Strategic Advisor*

2015 – Present

Clinical stage company developing therapies for respiratory and neurologic disorders, including opioid induced respiratory depression, spinal cord injury, and epilepsy.

- Led clinical development and strategic partnering for the company's Ampakine programs and opened its first IND.
- **Helped obtain two SBIR grants totaling \$4.8M.** Secured non-dilutive funding as strategic advisor, including a \$1.8M grant for a human clinical trial of CX1739 in spinal cord injury and a \$3M grant funding preclinical toxicology to support an IND filing.

### My Story (Direct 1 Communications) | *Consultant, Business Development & Corporate Alliances*

2023 – Present

Precision patient education company converting an individual patient's medical record into a short, personalized animated video.

- Developing the AI operational system and opening healthcare system relationships for implementation in targeted therapeutic and surgical settings.

### Hackensack Meridian Health | *Consultant; Board of Community Advisors*

2012 – Present

One of the largest healthcare systems in New Jersey.

- Evaluated and reorganized clinical research operations, developed department level strategic plans, and authored the Oncology Research Plan for the Cancer Center. Current member of the Board of Community Advisors.

## SELECTED EXECUTIVE & OPERATING LEADERSHIP

---

### **NuGenerex Immuno-Oncology & Generex Biotechnology** | *EVP, R&D / Chief Operating Officer*

- Completed M&A transactions and built a vaccine pipeline in oncology and infectious disease.
- **In response to SARS-CoV-2**, my team designed, patented, and developed a novel COVID-19 vaccine on the li-Key platform, completing fill and finish for clinical trial supply in 18 months.

### **intelliSanté Corporation** | *Founder, President & Director*

- Designed and launched C3HealthLink, a HIPAA compliant, cloud based platform integrating primary care and mental health services, with emphasis on patient activation, collaborative care, self-management, and outcomes analytics. Led all business development.

### **ClinPro, Inc.** | *President*

Full service CRO formed through the merger of three specialty practices in data management, statistics, and clinical operations.

- Signed five strategic alliance partnerships and multiple business development agreements with pharma, biotech, and medical device companies, and opened European and Japanese offices.
- Repositioned the company as a technology solutions provider, resulting in a five year, seven study partnership with a medical device company.

### **Aurora Capital** | *Entrepreneur-in-Residence*

Boutique biotechnology and life science investment bank, New York, NY.

- Evaluated dozens of early stage biopharmaceutical companies, provided strategic M&A services, and co-founded Xintria Pharmaceutical Corporation and RespireRx Pharmaceuticals with the Aurora partners.

## EARLIER CAREER HIGHLIGHTS

---

**SCP Communications, Inc.**, *Corporate VP / General Manager, Clinical Programs*. Grew the company to a \$75M business and made it the premier launch partner in pharma. Built and managed clinical launch programs for blockbusters including Lipitor, Avandia, Accolate, Tequin, Biaxin, and Meridia, and participated in the start-up of Medscape, then the leading medical website.

**Roche**, *Research Scientist, Protein Structure/Function Laboratory*. Member of the AIDS Research Task Force; purified and characterized the HIV-1 regulatory proteins rev and tat, published in PNAS and the Journal of Virology.

**Integrated Genetics (now Genzyme)**, *Scientist, Protein Engineering*. Established the Protein Engineering Department and developed and patented a second generation TPA with increased half-life. The patent generates ongoing royalties to Genzyme from Genentech on sales of TNKase.

**Kline Group**, *BD Manager, International Life Science Consulting*. Founded the firm's life science and biotechnology practice, delivering strategic planning, competitive intelligence, and licensing projects for pharma, biotech, and agrochemical clients.

**In Vivo**, *Director, Business Development*. Directed new business, client relations, and marketing for a specialty CRO focused on Phase IV medical marketing programs in CNS, oncology, and anti-infectives.

## SELECTED PATENTS & APPLICATIONS

---

**Semi-glycosylated Variants of TPA with Increased Half-life**. US 5,344,773; European 85306957.3; Japan 1-214-13.

**Multi-Targeting li-Key Peptide Vaccines Against SARS-CoV-2**. US Application 63/130,822, December 2020.

**Compositions and Methods for Treating Spinal Cord Injuries**. USPTO Patent application # 20240100023. March 2024.

## SELECTED PUBLICATIONS

---

Nalin C.M., Purcell R.D., et al. Purification and Characterization of Recombinant rev Protein of HIV-1. Proceedings of the National Academy of Sciences, Vol. 87, October 1990.

Ruben S., Purcell R., et al. Structural and Functional Characterization of HIV-1 tat Protein. Journal of Virology, January 1989.

Purcell R., Lynch G., Gall C., et al. Brain Vacuolation from the Type II Ampakine CX717 is an Artifact of Chemical Reaction with Tissue Fixatives. Toxicological Sciences, December 2017.

Krystal A., Greer J., Purcell R., et al. Antagonism of Remifentanyl-Induced Respiratory Depression by CX1739 (OIRD). SLEEP, Annual Meeting of the American Academy of Sleep Medicine, 2017.

Radin D., Purcell R., Lippa A. Oncolytic Properties of Ampakines In Vitro. Anticancer Research, January 2018.

*Additional peer-reviewed publications on Ampakine pharmacology and health technology available on request.*

## BOARD, ADVISORY & ACADEMIC APPOINTMENTS

---

**College Achieve Public Schools**, *Director of Strategic Initiatives; past Chairman, Board of Trustees*. Nonprofit charter network serving 3,600 K–12 students across three NJ communities; led strategy and financing for STEAM education initiatives.

**Monmouth University**, *Adjunct Professor, School of Science*. Built and taught The Business of Biotechnology from the Bench to the Market (BY360).

## EDUCATION

---

**Princeton University** — B.A., Biochemical Sciences. Thesis: Characterization of Nerve Growth Factor Receptor.

**Rutgers Graduate School of Management** — MBA program, Marketing & Finance.